CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 04 May 2017
Price : $35 *
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 31 Aug 2018 Biomarkers information updated
- 02 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2014 Status changed from not yet recruiting to recruiting.